Roche launches cobas MRSA/SA test in Europe

9 January 2014 (Last Updated January 9th, 2014 06:30)

Roche has launched the cobas MRSA/SA test for the early, simultaneous detection of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (SA) from nasal samples.

roche building

Roche has launched the cobas MRSA/SA test for the early, simultaneous detection of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (SA) from nasal samples.

The test is designed to run on the cobas 4800 system and detects both organisms from a single specimen, providing accurate and reliable results for effective prevention and control of MRSA/SA infections.

Roche Molecular Diagnostics Head Paul Brown said with the addition of the cobas MRSA/SA test, the company offers clinicians a sustainable molecular test that will aid in the overall management of hospital-acquired infections.

"The cobas MRSA/SA Test combines laboratory procedures with automation, which provides labs with a simplified workflow through primary vial loading," Brown said. "This approach requires less hands-on time and reduces the chance of error, which leads to better patient management."

The test can process specimens using one of the fastest, most advanced real-time polymerase chain reaction (PCR) amplification and detection.

The cobas 4800 system is reportedly the only CE-IVD marked system that offers the flexibility to run sexually transmitted infection and HAI tests simultaneously on a single platform.

"Successful initiatives have led to a decrease in the rate of MRSA in many institutions, requiring optimal sensitivity and specificity for identifying true carriers."

According to the company, the streamlined workflow can help labs reduce time and costs, as well as improving the turnaround period.

University Hospital Regensburg Institute of Medical Microbiology and Hygiene professor Dr Udo Reischl said the fight against healthcare associated infections (HAIs) continues to develop.

"Successful initiatives have led to a decrease in the rate of MRSA in many institutions, requiring optimal sensitivity and specificity for identifying true carriers," Dr Reischl said.

"The cobas MRSA/SA Test demonstrates excellent performance in detecting diverse MRSA strains from around the world, which provides confidence in identifying infected patients the first time they are evaluated."

The cobas 4800 system's expanding menu currently includes the cobas HSV 1 and 2 Test, cobas CT/NG Test (chlamydia/gonorrhea),cobas HPV Test, cobas BRAF V600 Mutation Test and the cobas EGFR Mutation Test.


Image: Aerial view of Roche Basel from south with river Rhine, Switzerland. Photo: courtesy of F Hoffmann-La Roche Ltd.